Bringing the FDA's information to market

Archives of Internal Medicine

Volumn 169, Issue 21, 2009, Pages 1985-1987

  Woloshin, Steven ^a   Schwartz, Lisa M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; IBUPROFEN; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

BUDGET; CARDIOVASCULAR DISEASE; CONSUMER; DRUG COST; DRUG MARKETING; DRUG SAFETY; EDEMA; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; HYPERTENSION; LIVER TOXICITY; NEPHROTOXICITY; NOTE; PRESCRIPTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ADVERTISING AS TOPIC; CYCLOOXYGENASE 2 INHIBITORS; DRUG INDUSTRY; DRUG LABELING; DRUG PRESCRIPTIONS; HUMANS; INFORMATION DISSEMINATION; LACTONES; META-ANALYSIS AS TOPIC; MYOCARDIAL INFARCTION; SAFETY-BASED DRUG WITHDRAWALS; SULFONES; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 73349107798     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.399     Document Type: Note

References (18)

1. Gagnon M-ALJ, Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med. 2008; 5(1):e1. doi:10.1371/journal.pmed.0050001.
2. Bradford WD, Kleit A, Nietert P, Steyer T, McIlwain T, Ornstein S. How directto-consumer television advertising for osteoarthritis drugs affects physicians' prescribing behavior. Health Aff (Millwood). 2006;25(5):1371-1377.
3. Weppner WG, Hollon MF, Chew LD, Larson EB. Direct-to-consumer offers for free and discounted medications on the Internet: a content analysis of "e-samples". Arch Intern Med. 2009;169(21):2024-2030.
4. Law MR, Soumerai SB, Adams AS, Majumdar SR. Costs and consequences of direct-to-consumer advertising for clopidogrel in Medicaid. Arch Intern Med. 2009;169(21):1969-1974.
5. US Food and Drug Administration. Drug approval package: Vioxx (rofecoxib) tablets: application No. 021042. http://www.accessdata.fda.gov/drugsatfda-docs/ nda/99/021042-52-Vioxx.cfm. Accessed September 9, 2009.
6. Psaty BM. Testimony before United States Senate Committee on Finance: FDA, Merck, and Vioxx: putting patient safety first? http://finance.senate.gov/ hearings/testimony/2004test/111804bptest.pdf. Accessed September 9, 2009.
7. US Food and Drug Administration. Drug approval package: Vioxx (rofecoxib): application Nos. 021045 and 021052: medical review (part 7). http://www.accessdata.fda.gov/drugsatfda-docs/nda/99/021042-52-vioxx-medr-P7. pdf. Accessed September 23, 2009.
8. PharmaLive.com. Direct-to-consumer advertising: analysis of DTC spend by brand, company and media: special report: June 2009. http://www.pharmalive.com/ special-reports/sample.cfm?reportID=276. Accessed September 8, 2009.
9. United States Food and Drug Administration. FDA advisory committee briefing document: NDA 21-042, s007: medical officer's gastroenterology review, February 8, 2001. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2-03-med. pdf. Accessed September 8, 2009.
10. Bombardier C, Laine L, Reicin A, et al; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343(21):1520-1528, 2, 1528.
11. United States Food and Drug Administration. FDA advisory committee briefing document: NDA 21-042, s007: medical officer's cardiovascular review, February 8, 2001. http://www.fda.gov/ohrms/dockets/AC/01/briefing/3677b2-06- cardio.pdf. Accessed September 8, 2009.
12. Waxman HA. Marketing of Vioxx to physicians [memorandum to the Democratic members of the Government Reform Committee, May 5, 2005]. http://oversight. house.gov/documents/20050505114932-41272.pdf. Accessed September 8, 2009.
13. Merck & Co Inc. VIOXX (rofecoxib tablets and oral suspension) [revised label, April 11, 2002]. http://www.accessdata.fda.gov/drugsatfda-docs/ label/2002/21042s7lbl.pdf. Accessed September 8, 2009.
14. Wilkes MS, Doblin B, Shapiro MF. Pharmaceutical advertisements in leading medical journals. Ann Intern Med. 1992;116(11):912-919.
15. Woloshin S, Schwartz LM, Tremmel J, Welch HG. Direct-to-consumer advertisements for prescription drugs: what are Americans being sold? Lancet. 2001;358(9288):1141-1146.
16. Schwartz LM, Woloshin S, Welch H. Using a drug facts box to communicate drug benefits and harms: two randomized trials. Ann Intern Med. 2009;150(8):516-527.
17. PAL(Prescription Access Litigation). Current lawsuits: Vioxx: background. http: //www.prescriptionaccess.org/lawsuitssettlements/current-lawsuits ?id=0028. Accessed September 8, 2009.
18. Committee on Appropriations. Committee Report 4 of 48-Senate Report 107-223 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Bill, 2003. http://thomas.loc.gov/cgi-bin/ cpquery/4?&item=4&&sid=TSOPMHseG&&hd-count= 48&&xform-type=0&&maxdocs=5000&&refer=&&r-n= sr223.107&&dbname=cp107&&w-p=AGRICULTURE++RURAL+DEVELOPMENT& attr=0&&w -p=fda&attr=1700&&sid=TSOPMHseG&&sel=TOC- 521693&. Accessed September 8, 2009.